Xenpozyme™ (olipudase alfa-rpcp) – New orphan drug approval
August 31, 2022 - The FDA announced the approval of Sanofi’s Xenpozyme (olipudase alfa-rpcp), for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.
Download PDF
